Back to Trials
NCT07145515NARecruiting

Enhancing Heart Allograft Function With the OCS Heart System Trial

TransMedics

Start Date

1/1/2026

Completion Date

7/30/2027

Summary

This trial is designed to evaluate the safety and effectiveness of the novel OCS Solution and OCS Functional Enhancer (OFE) to support FDA approval in both DBD and DCD heart transplantation. In addition, this trial will evaluate the performance of the novel OCS Solution and OFE compared to Static Cold Storage (SCS) in DBD heart transplantation to potentially demonstrate superiority.

Eligibility Criteria

Age Range: 18 years to No maximum

Part A - DCD Donor Hearts \& DBD Donor Hearts Initially Deemed Unsuitable for Cold Storage (Current Approved Indications): Donor Inclusion Criteria * Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room. * All DCD donors eligible for functional warm ischemic time criteria ≤ 30 minutes. WIT defined as time from when mean systolic blood pressure (SBP) is \<50mmHg (sustained for at least 5 minutes) to aortic cross clamp and administration of old cardioplegia in the donor. * DBD donor hearts with an expected cross clamp of ≥ 4 hours * DBD donor hearts with any of the following organ quality concerns, regardless of cross clamp time: * Donor age ≥ 40 years old * Unknown downtime * Insignificant CAD * LVEF ≤ 50% Donor Exclusion • Moderate to severe aortic incompetence Part B - DBD Donor Hearts Currently Used with Cold Storage (New Indication): Donor Inclusion Criteria * Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room. * Eligible for randomization to OCS or SCS treatment arms. * DBD donor hearts with an expected cross clamp time of \< 4 hours. Donor Exclusion * Moderate to severe aortic incompetence * DBD donor with any of the following organ quality concerns: * Donor age ≥ 40 years old * Unknown downtime * Insignificant CAD * LVEF ≤ 50% Recipient Eligibility Criteria (for Part A and B Cohorts) Inclusion * Signed informed consent document and authorization to use and disclose protected health information * Heart transplant candidate * Age ≥ 18 years old Exclusion • Participant in any other interventional clinical or investigational trials/programs that may confound the outcomes of this trial

Interventions

DEVICE

OCS Heart

OTHER

Static Cold Storage (SCS)

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Heart Transplant

Locations

University of California San Francisco

San Francisco, California 94143

United States

Tampa General Hospital

Tampa, Florida 33606

United States

Massachusetts General Hospital

Boston, Massachusetts 02114

United States

Mount Sinai

New York, New York 10029

United States

Columbia University Irving Medical Center/ New York Presbyterian Hospital

New York, New York 10032

United States

Westchester Medical Center

Valhalla, New York 10595

United States

Duke University

Durham, North Carolina 27710

United States

Baylor Scott and White

Dallas, Texas 75226

United States